Objective
The majority of critically ill children admitted to Paediatric Intensive Care Units (PICU) will require sedation
and analgesia which is commonly achieved with a combination of an benzodiazepine and an opioid. However,
these agents have a significant side-effect profile, including tolerance, withdrawal and respiratory/circulatory
depression. Clonidine is commonly used for sedation in PICU and recommended by guidelines in various
countries although there is a lack of evidence regarding it safety and efficacy in this setting. The need for safety
and efficacy data as well as an age appropriate formulation for clonidine has been realised and clonidine is
included in the EMA “Revised Priority List for Studies into Off-patent Medicinal Products”. Thus this proposal
addresses an important paediatric therapeutic need. It is designed to fullfill the requirements for most ethical
research in the paediatric population considering risk minimisation for patients, avoiding unnecessary studies and
make use of already available data as outlined in the Paediatric Regulation (EC) No 1901/2006. The objectives
of this project are a) to develop an age appropriate formulation of clonidine suitable for sedation of children in
PICU b) to conduct a randomised, phase III, double-blind, active-controlled parallel group clinical trial of clonidine
vs midazolam in patients from birth to 18 years to establish the efficacy and safety, including long-term outcomes
and dose-dependent effects of clonidine and c) to establish an European consensus guideline for sedion of
critically ill children. The ultimate goal is to use these data and to apply for a PUMA. On this basis a Paediatric
Investigation Plan (PIP) has been approved by the EMA in February 2013 and is reflected in the work plan of
CloSed. The project will increase the availability of paediatric medicines, foster the conduct of clinical trials in
children and establish international paediatric research collaborations.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences clinical medicine critical care medicine
- medical and health sciences clinical medicine paediatrics
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-HEALTH-2013-INNOVATION-1
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
91054 ERLANGEN
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.